<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932928</url>
  </required_header>
  <id_info>
    <org_study_id>H-2011-062-117</org_study_id>
    <nct_id>NCT04932928</nct_id>
  </id_info>
  <brief_title>Patient-Driven Lifestyle Modification Using FreeStyle Libre in Type 2 Diabetes Patients</brief_title>
  <acronym>PDF</acronym>
  <official_title>Patient-Driven Lifestyle Modification Using FreeStyle Libre in Type 2 Diabetes Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to provide medical nutritional therapy to patients with type 2 diabetes who are on&#xD;
      oral hypoglycemic agents or on basal insulin only and monitor the glycemic response with&#xD;
      flash glucose monitoring or self-monitoring of blood glucose.&#xD;
&#xD;
      Specifically, this is a randomized, open-label, controlled study where half of the study&#xD;
      participants will have FreeStyle Libre device on for 12 weeks and compare the change in&#xD;
      glycated hemoglobin (HbA1c) value with the patients in the control group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects: 126 patients with type 2 diabetes mellitus Scheme: Multi-center, Randomized,&#xD;
      open-label, controlled study&#xD;
&#xD;
      This study is referred to as the &quot;Patient-Driven lifestyle modification using FreeStyle Libre&#xD;
      in type 2 diabetes patients&quot;, also known as the PDF study.&#xD;
&#xD;
      It will assess potential benefits of using Continuous Glucose Monitoring (CGM) versus Self&#xD;
      Monitoring of Blood Glucose (SMBG) when combined with personalized education on lifestyle&#xD;
      modification in people with type 2 diabetes. Specifically, we will investigate patients who&#xD;
      have an elevated HbA1c between 7.0 - 10.0% who are not using prandial insulin.&#xD;
&#xD;
      Potential participants will be screened from routine outpatient clinic visits, will be&#xD;
      randomized to either the CGM or SMBG group in a 1:1 ratio. Participants from both groups will&#xD;
      receive education on lifestyle modification and will be reminded every 4 weeks with&#xD;
      structured phone visits. Study will be completed at the visit on 12 weeks of follow up with&#xD;
      the same laboratory examinations (including HbA1c) and survey from the baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2021</start_date>
  <completion_date type="Anticipated">March 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Between group differences (CGM and SMBG) for the change in HbA1c from baseline to Month 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean fasting glucose</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Between group differences (CGM and SMBG) for the change in fasting glucose from baseline to Month 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Between group differences (CGM and SMBG) for the change in body weight from baseline to Month 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Between group differences (CGM and SMBG) for the change in blood pressure from baseline to Month 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Between group differences (CGM and SMBG) for the change in waist circumference from baseline to Month 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipid level</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Between group differences (CGM and SMBG) for the change in lipid level (total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol) from baseline to Month 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Korean Version of Revised Summary of Diabetes Self-Care Activities Questionnaire (SDSCA-K) survey score</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Between group differences (CGM and SMBG) for the change in survey score from baseline to Month 3</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in CGM time in target range</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Change in CGM time in target range 70-180 mg/dL from baseline to Month 3 in the CGM group</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in CGM time-hyperglycemic</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Change in CGM time in time above target range, defined as &gt;250 mg/dL from baseline to Month 3 in the CGM group</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in CGM time-hypoglycemic</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Change in CGM time in time below target range, defined as &lt;70 mg/dL (level 1) and &lt; 54 (level 2) from baseline to Month 3 in the CGM group</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in CGM glucose variability</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Change in CGM glucose variability measured by the coefficient of variation from baseline to Month 3 in the CGM group</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Lifestyle Risk Reduction</condition>
  <arm_group>
    <arm_group_label>FreeStyle Libre (CGM) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: FreeStyle Libre (ver 1.0) Education on lifestyle modification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Self Monitoring of Blood Glucose (SMBG) Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Device: Blood glucose meter Education on lifestyle modification</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FreeStyle Libre</intervention_name>
    <description>Flash glucose monitoring + Education on lifestyle modification</description>
    <arm_group_label>FreeStyle Libre (CGM) Group</arm_group_label>
    <other_name>Education on lifestyle modification</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood glucose meter</intervention_name>
    <description>Self monitoring of blood glucose + Education on lifestyle modification</description>
    <arm_group_label>Self Monitoring of Blood Glucose (SMBG) Group</arm_group_label>
    <other_name>Education on lifestyle modification</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 19-80&#xD;
&#xD;
          -  Diagnosed with type 2 diabetes mellitus (DM)&#xD;
&#xD;
          -  Uncontrolled type 2 DM: HbA1c 7.0-10.0%&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with other types of diabetes mellitus (i.e. Type 1 DM)&#xD;
&#xD;
          -  Use of prandial insulin&#xD;
&#xD;
          -  Change in diabetes medication in the preceding 3 months&#xD;
&#xD;
          -  Pregnant/lactating women&#xD;
&#xD;
          -  Addiction to drugs and alcohol&#xD;
&#xD;
          -  Use of medications that result in drug-induced hyperglycemia (i.e. steroid)&#xD;
&#xD;
          -  Severe liver disease&#xD;
&#xD;
          -  End-stage renal disease (i.e. on dialysis)&#xD;
&#xD;
          -  Unable to wear CGM devices due to dermatologic side effects (i.e. severe burn,&#xD;
             inflammation, active skin infection, severe skin reactions, hypertrichosis, etc.)&#xD;
&#xD;
          -  Conditions that impact the stability of HbA1c measurement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Min Cho, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hun Jee Choe, MD</last_name>
    <phone>82-2-2072-1965</phone>
    <email>hunjeechoe@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young Min Cho, MD, PhD</last_name>
    <phone>82-2-2072-1965</phone>
    <email>ymchomd@snu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Min Cho, MD, PHD</last_name>
      <phone>82-2-2072-1965</phone>
      <email>ymchomd@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 13, 2021</study_first_submitted>
  <study_first_submitted_qc>June 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>June 13, 2021</last_update_submitted>
  <last_update_submitted_qc>June 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

